The National Health Service (NHS) is initiating trials of ultra-fast brain scans and other novel technologies in an effort to expedite the diagnosis of dementia. Researchers aim to cut the time patients spend in an MRI scanner from approximately 20 minutes to as little as six minutes, while maintaining diagnostic accuracy.
These advanced scanning techniques are becoming increasingly crucial for accurate dementia diagnosis, determining eligibility for new Alzheimer's treatments, and monitoring their efficacy. However, a severe shortage of MRI scanners in the UK has created a significant bottleneck, leading to extensive delays in diagnosis.
Cutting scan times by an estimated 70% could fundamentally improve patient access, reduce costs, and enhance the tolerability of the imaging process. This initiative is part of a broader £80 million taxpayer-funded research program testing nine new technologies within the NHS. The overarching goal is to drastically reduce the time from referral to diagnosis, targeting 92% of individuals receiving a diagnosis within 18 weeks, a significant increase from the current rate of 60%, where diagnoses can often take over a year.
Early diagnosis offers several benefits, including a reduced likelihood of emergency hospital admissions, delayed need for extensive care support, and lessened impact on the NHS. It can also enable patients to commence treatment sooner and make informed decisions regarding their work, finances, and family life.
The ultra-fast scan trial is being led by University College London in collaboration with MRI scanner manufacturers Philips, Siemens, and GE across 20 NHS sites. The research is funded by the Department for Business, Innovation, Science and Trade (BIST) through UK Research and Innovation (UKRI).
Other technologies under investigation include remote monitoring of cognitive decline via digital devices, home monitoring equipment with body sensors to detect behavioral changes, and blood biomarker tests. Health minister Karin Smyth emphasized the importance of timely diagnosis for symptom management and access to support, stating that the government is backing research projects that offer hope for individuals living with dementia.
UKRI is employing a 'fail-fast' approach, where projects must demonstrate results and achieve milestones to secure continued funding, prioritizing those with the most promise. Andy Hill, Health Mission Challenge Director at UKRI, noted that improved diagnostic tools will help individuals with dementia manage symptoms, access earlier treatment, and plan for their futures, ultimately enhancing the lives of patients, families, and carers.
Hilary Evans-Newton, Chief Executive of Alzheimer's Research UK, highlighted that the current diagnostic waiting times are too long and that this program aims to accelerate the adoption of effective innovations. She stressed the importance of faster, accurate diagnosis for the effectiveness of new medicines, particularly in the early stages of the disease. Dr. Richard Oakley, Associate Director of Research and Innovation at the Alzheimer's Society, added that a significant portion of individuals living with dementia in the UK do not have a diagnosis, missing out on crucial treatment and support. He urged the government to establish a national 18-week target from referral to diagnosis to match the ambition of this technological advancement.